Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobicistat Boosted Venetoclax + Azacitidine in Unfit AML Patients
NCT06014489Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cobicistat in acute myeloid leukemia (AML), sponsored by HOVON. Started Jan 2024; status: recruiting.
02
Drugs
cobicistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06014489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014489.